Expertise in
39
conditions

Dr. Gary V. Burton

Oncology
Lsuhsc Shreveport
1501 Kings Hwy, 
Shreveport, LA 
Accepting New Patients
Offers Telehealth
Expertise in
39
conditions
Lsuhsc Shreveport
1501 Kings Hwy, 
Shreveport, LA 

Overview

Gary Burton is an Oncologist practicing medicine in Shreveport, Louisiana.

Dr. Burton is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

He is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 31 clinical trials. Dr. Burton is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in LA

Hospital Affiliations

Ochsner Lsu Health Shreveport
Desoto Regional Health System
Ochsner Lsu Health Shreveport-St Mary Medical Cent

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Lsuhsc Shreveport
1501 Kings Hwy, Shreveport, LA 71103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Radiation, Other
Study Phase: Phase 3
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
View 9 Less Clinical Trials

22 Total Publications

Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.
Journal: JCO oncology practice
Published: April 28, 2026
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Gynecologic Oncology Associates - South

2508 Bert Kouns Industrial Loop Ste 300, 
Shreveport, LA 
 (6.5 miles away)
318-545-4565
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Destin Black is an Oncologist practicing medicine in Shreveport, Louisiana. Dr. Black is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Vulvar Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, and Splenectomy. Dr. Black is currently accepting new patients.

Expertise in
119
conditions
Dr. Anil Veluvolu
Hematology | Oncology
Expertise in
119
conditions
Dr. Anil Veluvolu
Hematology | Oncology
Referral may be required

Willis Knighton Hematology/Oncology North

2600 Kings Hwy Ste 300, 
Shreveport, LA 
 (1.0 miles away)
318-333-6270
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anil Veluvolu is a Hematologist and an Oncologist practicing medicine in Shreveport, Louisiana. Dr. Veluvolu is highly rated in 119 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Colorectal Cancer, Lynch Syndrome, and Liver Embolization. Dr. Veluvolu is currently accepting new patients.

Expertise in
51
conditions
Dr. Sakeer Hussain
Hematology | Oncology
Expertise in
51
conditions
Dr. Sakeer Hussain
Hematology | Oncology
Referral may be required

Lsuhsc Shreveport

1501 Kings Hwy, 
Shreveport, LA 
 (0.1 miles away)
318-813-1057
Languages Spoken:
English, Burmese, Hindi, Malay, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Sakeer Hussain is a Hematologist and an Oncologist practicing medicine in Shreveport, Louisiana. Dr. Hussain is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Chronic Familial Neutropenia, Paget Disease of the Breast, Colorectal Cancer, and Lynch Syndrome. Dr. Hussain is currently accepting new patients.

Frequently Asked Questions about Dr. Gary V. Burton

How do I make an appointment with Dr. Gary V. Burton?

You can book an appointment with Dr. Gary V. Burton by calling their office at 318-813-1431. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gary V. Burton a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gary V. Burton is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gary V. Burton specialize in?

While Dr. Gary V. Burton is a Oncology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Gary V. Burton participate in research or clinical trials?

Yes. Dr. Gary V. Burton has published 22 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Gary V. Burton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gary V. Burton accept my insurance?

Dr. Gary V. Burton accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 318-813-1431 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Burton's expertise for a condition
ConditionClose
    View All 34 Advanced Conditions
    View All 72 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile